BeOne Medicines (SHA:688235, HKG:6160) posted first-half attributable net profit of 3.27 billion yuan, up 627% from 449.8 million yuan the previous year.
Basic earnings per share jumped to 2.26 yuan from 0.32 yuan, according to a Thursday filing with the Shanghai bourse.
Operating revenue climbed 27% year over year to 22.2 billion yuan from 17.5 billion yuan.
Shares of the oncology company fell 5% in recent trade on the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.